Health
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Ca
About this update from Revolution Medicines, Inc.
[{"type":"image","alt":"Revolution Medicines, Inc.","displaySize":"","headline":null,"caption":"Revolution Medicines, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/5fd0263e2225a1c8e4ed2273768d4bce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rZNLi5mJW78ZE0xMtIm2pA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/5fd0263e2225a1c8e4ed2273768d4bce","width":300,"height":100}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting and will be featured in a plenary oral presentation today, April 19, 2026, at 1:30 p.m. PDT.","length":628,"tagName":"p"},{"type":"text","content":"“Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic oncology at UC Davis Comprehensive Cancer Center and principal investigator for the RMC-9805-001 trial. “The manageable safety profile and evidence of clinical activity in this Phase 1 trial are encouraging and support the continued clinical development of zoldonrasib.”","length":469,"tagName":"p"},{"type":"text","content":"“We believe these updated data further strengthen the profile of zoldonrasib as a potentially important targeted therapy for patients with RAS G12D non-small cell lung cancer where historical treatment options, such as chemotherapy, have offered limited benefit, and are often associated with considerable toxicity,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “The emerging profile supports advancing zoldonrasib across monotherapy and combination settings in lung cancer and other RAS G12D-driven cancers.”","length":540,"tagName":"p"},{"type":"text","content":"Summary of Phase 1 Zoldonrasi...